Scarica l'app Stockscreener
19.14
0.42%
0.08
Dopo l'orario di chiusura:
19.15
0.010
+0.05%
Jade Biosciences Inc Borsa (JBIO) Ultime notizie
JBIO: JADE101 leads a robust pipeline with best-in-class data and rapid path to market in IgA nephropathy - TradingView
Jade Biosciences at citigroup summit: fast-track bet on igan By Investing.com - Investing.com India
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 By Investing.com - Investing.com South Africa
Jade Biosciences at Wells Fargo conference: pipeline bets on JADE 101 - Investing.com
Jade Biosciences Company Profile & Introduction - Moomoo
JADE BIOSCIENCES, INC. : CLEAR STREET RAISES TARGET PRICE TO $48 FROM $25 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Clear Street Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - Moomoo
LifeSci Capital Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Jade Biosciences to Participate in Upcoming Conferences - Yahoo Finance
Jade (JBIO) Financial Update: The Bottom-Line Figure Trails Its Comparison in the Latest Session; Investor Response: Shares End With Little Net Change at the CloseEarnings Quality Analysis - vinanet.vn
Bio Ionic Partners with Ulta Beauty on Limited Edition Jade Dream Collection - finance.yahoo.com
Jade Biosciences (NASDAQ:JBIO) Shares Gap UpWhat's Next? - MarketBeat
Jade Biosciences advances JADE101 for IgAN with promising Phase 1 results and Phase 2 data due in 2027 - Pluang
Jade Biosciences: Duration Is The Real Product (NASDAQ:JBIO) - Seeking Alpha
Jade Biosciences (JBIO) Stock Analysis Report | Financials & Insights - Benzinga España
H.C. Wainwright Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Stifel Maintains Jade Biosciences(JBIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
HC Wainwright Analysts Increase Earnings Estimates for JBIO - MarketBeat
Jade Biosciences (JBIO) Shares Just Moved, So What Is Going On? - Sahm
Jade Biosciences (JBIO) Advances 2.4% to $22.89 as Buyers Defend Key Support ZoneFlat Correction - vinanet.vn
Renaissance Technologies LLC Boosts Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jefferies Maintains Jade Biosciences(JBIO.US) With Buy Rating, Raises Target Price to $48 - Moomoo
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX) - theglobeandmail.com
Wedbush Maintains Jade Biosciences(JBIO.US) With Buy Rating, Announces Target Price $47 - Moomoo
A Quick Look at Today's Ratings for Jade Biosciences(JBIO.US), With a Forecast Between $42 to $77 - Moomoo
Jade Biosciences Is Maintained at Buy by BTIG - Moomoo
Jade Biosciences (NASDAQ:JBIO) Given New $77.00 Price Target at BTIG Research - MarketBeat
Jade Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
JBIO SWOT Analysis: Financial Challenges and Development Opportu - GuruFocus
Jade Biosciences, Inc. Stock 12‑Month Price Target Raised to $46.44, Implies 111% Upside - TradingView
Wedbush raises Jade Biosciences price target on pipeline progress By Investing.com - Investing.com Australia
Wedbush raises Jade Biosciences price target on pipeline progress - Investing.com
Jade Biosciences Releases Q2 2026 Financial Results - AlphaStreet
Jade Biosciences Announces Q2 2026 Financial Results Highlighting Increased R&D and Asset Growth - Kalkine Media
Jade Biosciences Q2 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Jade Biosciences' Q2 Loss Narrows - marketscreener.com
Earnings Flash (JBIO) Jade Biosciences Posts Q2 Loss $0.76 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
Jade Biosciences reports Q2 net loss $55.8M, cash $461.2M; advances JADE101 to Phase 2/3 - TradingView
Jade Biosciences (NASDAQ: JBIO) boosts cash to $461M while loss widens - Stock Titan
Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Jade Biosciences reports $55.8 million Q2 net loss - Quiver Quantitative
Jade Biosciences Q2 net loss widens as costs rise - TradingView
Jade Biosciences Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView
Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - marketbeat.com
Jade Biosciences (NASDAQ:JBIO) Trading 10% HigherHere's What Happened - marketbeat.com
Jade Biosciences (NASDAQ:JBIO) Shares Down 4.2%Here's What Happened - MarketBeat
Orbimed Advisors LLC Sells 346,152 Shares of Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences (JBIO) Holds Near $20 Support as Biotech Sentiment WaversDemand Zone - vinanet.vn
Jade Biosciences Ord Shs (JBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
JBIO|Jade Biosciences Ord Shs|Price:21.670|Chg%:+0.320 - TradingKey
Affinity Asset Advisors LLC Decreases Holdings in Jade Biosciences, Inc. $JBIO - MarketBeat
Jade Biosciences, Inc. Revenue Breakdown – NASDAQ:JBIO - TradingView
Paradigm Biocapital Advisors LP Acquires Significant Stake in Ja - GuruFocus
Jade Biosciences Inc. (JBIO) Q1 2026 Earnings: Pre-Revenue Biotech Misses EPS Estimates as Development Costs WeighProfit Announcement - dars.gov.et
Paradigm funds disclose significant Jade Biosciences (JBIO) ownership in Schedule 13G - Stock Titan
Jade Biosciences Inc. (JBIO) Climbs 1.67% as Stock Tests Near Resistance at $22.37Equity Put Call - vinanet.vn
Jade Biosciences Inc. (JBIO) Holds Steady Near Key Resistance as Trading Volume Remains CalmHull Moving Average - DonanımHaber
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):